Search
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.
Terazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Categories: Drugs Used in Benign Prostatic HypertrophyModified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalVaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).[L42660,L42670] … Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.
Synonyms: MVA-BNAsparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. … (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONAdapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigationalDifferin was later made available as 0.1% gel, cream, or lotion, or 0.3% gel products. On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel. … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.
Categories: Retinoids for Topical Use in AcneVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Avanafil
go.drugbank.com/drugs/DB06237Approved[L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113] … Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction.
Categories: Drugs Used in Erectile DysfunctionSynonyms: (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamideMecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalIn 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Amikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approved[F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population … M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil.
Synonyms: 1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin A, -D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-